Can we, should we, eradicate the meningococcus?

被引:11
|
作者
Maiden, Martin C. J. [1 ]
Frosch, Matthias [2 ]
机构
[1] Univ Oxford, Dept Zool, Oxford OX1 3PS, England
[2] Univ Wurzburg, Inst Fuer Hyg & Mikrobiol, D-97080 Wurzburg, Germany
基金
英国惠康基金;
关键词
Neisseria meningitidis; Vaccines; Epidemiology; Population biology; NEISSERIA-MENINGITIDIS; CARRIED MENINGOCOCCI; CONJUGATE VACCINE; SEROGROUP; DISEASE; IMMUNITY; IMMUNOGENICITY; DIVERSITY; EVOLUTION; VIRULENCE;
D O I
10.1016/j.vaccine.2011.12.068
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
The eradication of infectious agents is an attractive means of disease control that, to date, has been achieved for only one human pathogen, the smallpox virus. The introduction of vaccines against Neisseria meningitidis into immunisation schedules, and particularly the conjugate polysaccharide vaccines which can interrupt transmission, raises the question of whether disease caused by this obligate human bacterium can be controlled, eliminated, or even eradicated. The limited number of meningococcal serogroups, lack of an animal reservoir, and importance of meningococcal disease are considerations in favour of eradication; however, the commensal nature of most infections, the high diversity of meningococcal populations, and the lack of comprehensive vaccines are all factors that suggest that this is not feasible. Indeed, any such attempt might be harmful by perturbing the human microbiome and its interaction with the immune system. On balance, the control and possible elimination of disease caused by particular disease-associated meningococcal genotypes is a more achievable and worthwhile goal. (C) 2011 Elsevier Ltd. All rights reserved.
引用
收藏
页码:B52 / B56
页数:5
相关论文
共 50 条
  • [31] Synthetic Biology: Now that We're Creators, What Should We Create?
    Cohan, Frederick M.
    CURRENT BIOLOGY, 2010, 20 (16) : R675 - R677
  • [32] Arthritis in Canada: What do we know and what should we know?
    Badley, EM
    JOURNAL OF RHEUMATOLOGY, 2005, 32 : 39 - 41
  • [33] Should we measure dyspnoea in everyone?
    Banzett, Robert B.
    O'Donnell, Carl R.
    EUROPEAN RESPIRATORY JOURNAL, 2014, 43 (06) : 1547 - 1550
  • [34] Towards a meningitis free world-Can we eliminate meningococcal meningitis? Contribution of the meningitis patient groups
    Davie, Sue
    Glennie, Linda
    Rowland, Kate
    VACCINE, 2012, 30 : B98 - B105
  • [35] What Should We Teach When We Teach about Women with Disabilities?
    Olkin, Rhoda
    WOMEN & THERAPY, 2014, 37 (1-2) : 94 - 108
  • [36] Can We Cure Atherosclerosis?
    Robinson, Jennifer G.
    Davidson, Michael H.
    REVIEWS IN CARDIOVASCULAR MEDICINE, 2018, 19 : S20 - S24
  • [37] Unusual global outbreak of monkeypox: what should we do?
    Zhu, Miaojin
    Ji, Jia
    Shi, Danrong
    Lu, Xiangyun
    Wang, Baohong
    Wu, Nanping
    Wu, Jie
    Yao, Hangping
    Li, Lanjuan
    FRONTIERS OF MEDICINE, 2022, 16 (04) : 507 - 517
  • [38] Cytomegalovirus: Should We Screen Pregnant Women for Primary Infection?
    Johnson, Julie M.
    Anderson, Brenna L.
    AMERICAN JOURNAL OF PERINATOLOGY, 2013, 30 (02) : 121 - 124
  • [39] Nanotechnology in adjuvants and vaccine development: what should we know?
    Assis, Bruna Rodrigues Dias
    da Silva, Caroline Dohanik
    Santiago, Marie Gabriele
    Ferreira, Lucas Antonio Miranda
    Goulart, Gisele Assis Castro
    NANOMEDICINE, 2021, 16 (29) : 2565 - 2568
  • [40] Diversity, innovation and entrepreneurship: where are we and where should we go in future studies?
    Charlie Karlsson
    Jonna Rickardsson
    Joakim Wincent
    Small Business Economics, 2021, 56 : 759 - 772